$INBS News

Intelligent Bio Solutions' Intelligent Fingerprinting Limited Has Been Granted European Patent Number EP3497617 Titled "SKINPRINT ANALYSIS METHOD AND APPARATUS".

Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action?

Intelligent Bio Solutions' Intelligent Fingerprinting Drug Screening Business Has Been ISO Recertified To The 13485:2016 Quality Management System Standard And Will Be Valid For Three Years

Intelligent Bio Solutions Completes Usability Study For Intelligent Fingerprinting Drug Screening System To Detect Opiate Codeine

Intelligent Bio Solutions Resolves All Cybersecurity, Software-Related Review Items For Its Upcoming FDA Submission

Intelligent Bio Solutions Completes Precision Testing For Its Intelligent Fingerprinting Drug Screening System To Detect Opiate Codeine

Intelligent Bio Solutions Starts Interference Study To Support FDA Submission For U.S. Market Clearance Of Its Intelligent Fingerprinting Drug Screening System For Codeine Detection

Intelligent Bio Solutions Initiates Multi-Site Method Comparison Study To Support FDA 510(k) Submission For US Market Clearance Of Intelligent Fingerprinting Drug Screening System For Opiate Codeine

Intelligent Bio Solutions Q3 EPS $(1.80) Up From $(4.40) YoY, Sales $1.060M Up From $728.867K YoY

Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results

Intelligent Bio Solution Launches Validation Study Targeting A Significant Reduction In The Time Required To Analyze Its Intelligent Fingerprinting Drug Screening System

Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified

Intelligent Bio Solutions Completes Penetration Testing As Part Of Its Upcoming FDA Submission

Intelligent Bio Solutions shares are trading lower. The company said it completed initial clinical Cut-off Study supporting its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine.

Intelligent Bio Solutions shares are trading lower. The company said it completed initial clinical Cut-off Study supporting its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine.

Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market

Intelligent Bio Solutions Completes Its Initial Clinical Cut-Off Trial For FDA 510(k) Submission For U.S. Market Clearance Of Its Intelligent Fingerprinting Drug Screening System

Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant

Intelligent Bio Solutions Adds Eighth European Patent To Portfolio, Secures Patent For Fingerprint Chemical Analysis With Fingerprint Deposition Volume

Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry